Oncology Today with Dr Neil Love

Featuring perspectives from Dr Deborah K Armstrong and Dr David M O’Malley, including the following topics:
Introduction (0:00)
PARP Inhibitors and Strategies Targeting Folate Receptor Alpha in Advanced Ovarian Cancer — Dr Armstrong (4:37)
Other Novel Agents and Strategies for the Treatment of Advanced Ovarian Cancer — Dr O’Malley (35:18)

CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, including the following topics:
Introduction (0:00)
Role of Anti-PD-1/PD-L1- and CLDN18.2-Directed Antibodies in the Management of Gastroesophageal Cancers — Dr Klempner (5:52)
Management of HER2-Positive Gastroesophageal Cancers — Dr Janjigian (28:20)

CME information and select publications

Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:
Introduction (0:00)
Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30)
Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33)

CME information and select publications

Featuring an interview with Prof Martin Reck, including the following topics:
Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00)
Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25)
Considerations with maintenance therapy for ES-SCLC (9:31)
Considerations with immunotherapy for ES-SCLC (13:12)
Curability of SCLC with systemic therapy (15:17)
Data with chemoimmunotherapy for patients with poor performance status (25:55)
Future developments in therapy for SCLC (30:11)
Rapid fire: Small Cell 101 (35:45)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics:
Introduction (0:00)
Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)
Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41)

CME information and select publications